Less than 1 min.Read

Resonance Health: Receives HepaFat FDA clearance

December 9, 2020

Resonance Health (RHT) has received a key clearance for its HepaFat product from the U.S. Food and Drug Administration (FDA)
The product essentially works as a non-invasive medical device which measures the volume fraction of fat in liver tissue
This approval from the FDA will also allow Resonance to market HepaFat for commercial distribution in the U.S.
The company’s CEO has labeled the 501(k) clearance an “outstanding result”
Company CEO Alison Laws also said the clearance is an important milestone for Resonance
Shareholders agree, with Resonance shares shooting up 41.9 percent and trading at 22 cents each